ArticleInternational journal of clinical and experimental medicine2015
MicroRNA-9 is a ponderable index for the prognosis of human hepatocellular carcinoma.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.Molecular medicine reports · 2018Pooled it
- Prognostic Value of microRNA-9 in Various Cancers: a Meta-analysis.Pathology oncology research : POR · 2017Pooled it
- Article
- Article
- Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition.International journal of biological sciences · 2020Article
- MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma progression by targeting HMGA2.FEBS open bio · 2019Article
- Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian PatientsAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Anti-miRNA oligonucleotides: A comprehensive guide for design.RNA biology · 2018Review
- Article
- MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.Oncology letters · 2018Article
- Article
- Article
- LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism.OncoTargets and therapy · 2017Article
- MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common primary malignant tumors of the liver worldwide; however, despite its significance, there is a lack of treatment methods and clear prognoses. MicroRNA-9 (miR-9) is known to play an important role in tumor tumorigenesis and progression. Talin-1, which plays a significant role in regulating the transmutation of carcinoma, has been demonstrated to be downregulated by miR-9 in epithelial ovarian cancer. In the present study, we researched the potential role of miR-9 in the prognosis of HCC. The expression levels of miR-9 and Talin-1 mRNA in HCC tissues (n = 60), adjacent non-cancerous tissues (n = 60), and normal liver tissues (n = 20) were detected using a real-time quantitative assay; protein expression levels of Talin-1 were detected using western blot. The expression levels of miR-9 were significantly higher in HCC tissues (P < 0.001) than in normal liver and adjacent non-cancerous tissues. These levels were significantly associated with tumor grade, tumor size, portal vein tumor thrombus, integral capsule, and 2.0-year disease-free survival rate (P < 0.05). High levels of miR-9 were strongly associated with the malignant progression of HCC, and overexpression of miR-9 is a risk factor that has a statistically significant effect on survival rate. miR-9 could play a role as an HCC tumor activator by regulating the expression of Talin-1; therefore, miR-9 might be a potentially valuable biomarker for the prognosis in HCC patients.
Indexed as
Identifiers
26770365PMC4694265W2413664317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.